What Tests Are Needed for TSC After Finding a Kidney AML?
At a Glance
Finding a kidney growth called an angiomyolipoma does not by itself prove tuberous sclerosis complex. If TSC is suspected or confirmed, genetic counseling and age-appropriate checks of the kidneys, brain, lungs, heart, skin, eyes, and teeth help find complications early.
In this answer
7 sections
If a kidney angiomyolipoma (AML) leads to a diagnosis of tuberous sclerosis complex (TSC), your medical care will expand beyond just monitoring your kidneys. Because TSC is a genetic condition that can affect multiple organs, you will need a coordinated, full-body assessment. However, finding out you have a multisystem diagnosis can feel overwhelming. It is important to know that having TSC does not mean you will experience every complication. A multidisciplinary care team will individualize your testing schedule based on your age, sex, and specific symptoms, so problems can be identified and treated early. A single kidney AML does not by itself establish a TSC diagnosis; instead, doctors use a combination of clinical criteria and genetic testing to confirm the diagnosis [1][2].
Genetic Counseling and Family Planning
A critical first step is meeting with a genetic counselor. They can discuss testing for changes in the TSC1 or TSC2 genes, which can clarify your diagnosis and help assess the risk for your family [1][2].
- Testing Limits: A negative blood test does not completely rule out TSC. Some people have “mosaic” forms of the condition (where the gene change is only in some cells) or deep gene changes that standard tests might miss, so additional sample testing may be needed [3][4].
- Family Implications: Because TSC is autosomal dominant, a known genetic variant has implications for parents, siblings, and children. Targeted testing can identify other family members who might need monitoring [2][5].
- Pregnancy: If you are planning a family, a counselor can explain reproductive options, including preimplantation genetic diagnosis and prenatal testing [6][7]. Women taking medications like mTOR inhibitors will need to discuss stopping them before pregnancy [8].
Kidney Monitoring and Treatments
While your care will expand, ongoing kidney management is essential.
- Imaging: Current guidelines recommend kidney imaging every 1 to 3 years to track AML growth [9][10]. An abdominal MRI (often with and without contrast, or a noncontrast protocol) is generally preferred over repeated CT scans to minimize your exposure to radiation over a lifetime [9][11].
- Lab Tests: Your team should check your blood pressure and measure your kidney function (using estimated glomerular filtration rate, or eGFR, and urine protein) at least once a year [12][13].
- Treatment Options: Monitoring guides kidney-sparing treatments. For asymptomatic, growing AMLs larger than 3 cm, medications called mTOR inhibitors are often recommended to shrink the tumor [14][15]. For higher-risk lesions or active bleeding, a procedure to block the tumor’s blood supply (embolization) or kidney-sparing surgery may be used [16][17].
Brain and Nervous System
TSC frequently affects the brain, making neurological evaluations a core part of care.
- Brain Imaging: An initial baseline brain MRI is important for everyone. For routine surveillance, an MRI is typically recommended every 1 to 3 years until age 25 to screen for benign brain tumors called subependymal giant cell astrocytomas (SEGAs) [1][18]. Although SEGAs are non-cancerous, they can grow and block the flow of cerebrospinal fluid, causing serious pressure in the brain [19][20].
- Seizures and EEG: Infants need a baseline electroencephalogram (EEG) and close serial monitoring for the first two years of life to catch abnormal electrical activity before visible seizures start [21][22]. Adults who do not have a history of seizures generally do not need routine EEGs unless new neurological symptoms occur [23].
- Mental Health: TSC is associated with learning, behavioral, and psychiatric challenges, collectively called TSC-associated neuropsychiatric disorders (TAND). Your care team should screen you annually using a TAND checklist; if issues are identified, this should lead to a fuller psychological or educational evaluation [24][1].
Lung Evaluation in Women
Women with TSC are at risk for a lung condition called lymphangioleiomyomatosis (LAM). Because estrogen is linked to LAM, symptoms can worsen during menstruation, pregnancy, or with estrogen-containing medications [25][26].
- Baseline Screening: Adult women should generally receive a baseline high-resolution chest CT scan and pulmonary function tests (PFTs) around age 18 or upon diagnosis [27][28]. PFTs measure airflow, lung volumes, and how well the lungs transfer gas [27][29].
- Follow-up: Because of cumulative radiation risks from CT scans, the schedule for repeat imaging and PFTs will be individualized based on your baseline results and symptoms [30].
Heart Assessments
Benign cardiac tumors called rhabdomyomas are a classic sign of TSC [31][32].
- Routine Checks: An electrocardiogram (ECG) is usually performed at diagnosis and periodically thereafter to check your heart’s electrical activity [31][33].
- Echocardiograms: This heart ultrasound is crucial for infants—where rhabdomyomas are most common and usually shrink on their own—but follow-up scans in adults depend on age, previous tumor findings, and symptoms [31][32].
Skin, Eyes, and Dental Care
- Dermatology: A detailed skin exam should be done at diagnosis and annually to monitor for specific rashes or growths. If lesions become symptomatic, you may be referred to a dermatologist for early treatment [34][35].
- Ophthalmology: An eye doctor should examine your eyes annually, often using special imaging like optical coherence tomography (OCT) to look for harmless growths on the retina (astrocytic hamartomas) [36][37].
- Dental: During twice-yearly checkups, your dentist should look for small pits in your tooth enamel and benign growths on your gums (oral fibromas) [38][39].
TSC Surveillance Quick Reference
| System | Baseline / At Diagnosis | Routine Follow-up | When to Seek Urgent Care |
|---|---|---|---|
| Genetics | Genetic counseling, TSC1/TSC2 testing | Discuss pregnancy options | N/A |
| Kidneys | Abdominal MRI; baseline eGFR and blood pressure | MRI every 1–3 years; annual lab/BP checks | AML Bleeding: Sudden severe flank/abdominal pain, visible blood in urine, marked weakness, dizziness, or fainting [40][41] |
| Brain | Brain MRI; infant baseline EEG | MRI every 1–3 years (until age 25); infant serial EEGs; annual TAND screen | SEGA/Pressure: New or worsening headaches, vomiting, vision changes, confusion, balance problems, or new seizures [19][20] |
| Lungs (Women) | High-resolution chest CT; baseline PFTs | Individualized CT/PFT schedule based on findings | Pneumothorax: Sudden chest pain or new/worsening shortness of breath [42][43] |
| Heart | ECG and Echocardiogram | Periodic ECG; Echo based on symptoms/history | Fainting, sustained palpitations, chest pain, unexplained breathlessness [1][32] |
By building a comprehensive care plan with your clinic coordinator or specialists, you can catch potential issues early and focus on treatments that protect your long-term health and quality of life.
Common questions in this guide
Does finding a kidney angiomyolipoma mean I have tuberous sclerosis complex?
What genetic tests are used when TSC is suspected?
What kidney tests and scans are needed after an AML is found?
What other organs should be checked for TSC?
How often are brain MRI and EEG tests needed in TSC?
Which symptoms after a kidney AML or TSC need urgent care?
Related questions
Show more
Get notified when new evidence is published on angiomyolipoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (43)
- 1
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.
Northrup H, Aronow ME, Bebin EM, et al.
Pediatric neurology 2021; (123()):50-66 doi:10.1016/j.pediatrneurol.2021.07.011.
PMID: 34399110 - 2
Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice.
Peron A, Au KS, Northrup H
American journal of medical genetics. Part C, Seminars in medical genetics 2018; (178(3)):281-290 doi:10.1002/ajmg.c.31651.
PMID: 30255984 - 3
Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.
Tyburczy ME, Dies KA, Glass J, et al.
PLoS genetics 2015; (11(11)):e1005637 doi:10.1371/journal.pgen.1005637.
PMID: 26540169 - 4
Targeted Genomic Sequencing of TSC1 and TSC2 Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal.
West HD, Nellist M, Brouwer RWW, et al.
Human mutation 2023; (2023()):4899372 doi:10.1155/2023/4899372.
PMID: 40225170 - 5
Fetal cardiac tumor: echocardiography, clinical outcome and genetic analysis in 53 cases.
Chen J, Wang J, Sun H, et al.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2019; (54(1)):103-109 doi:10.1002/uog.19108.
PMID: 29877000 - 6
Diagnosis of tuberous sclerosis complex in the fetus.
Dragoumi P, O'Callaghan F, Zafeiriou DI
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(6)):1027-1034 doi:10.1016/j.ejpn.2018.08.005.
PMID: 30279084 - 7
A novel TSC2 c.4511 T > C missense variant associated with tuberous sclerosis complex.
He S, Lv N, Bao H, et al.
BMC medical genetics 2020; (21(1)):180 doi:10.1186/s12881-020-01120-z.
PMID: 32917147 - 8
Healthcare provider recognition of pregnancy related risks and management considerations in patients with tuberous sclerosis complex.
Rose M, Ritter D, Gupta N, et al.
Orphanet journal of rare diseases 2024; (19(1)):4 doi:10.1186/s13023-023-03015-7.
PMID: 38166979 - 9
Renal manifestations of tuberous sclerosis complex: patients' and parents' knowledge and routines for renal follow-up - a questionnaire study.
Cockerell I, Guenin M, Heimdal K, et al.
BMC nephrology 2018; (19(1)):39 doi:10.1186/s12882-018-0835-3.
PMID: 29439672 - 10
Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex.
Buj Pradilla MJ, Martí Ballesté T, Torra R, Villacampa Aubá F
Clinical kidney journal 2017; (10(6)):728-737 doi:10.1093/ckj/sfx094.
PMID: 29225800 - 11
Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.
Kingswood JC, Belousova E, Benedik MP, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(3)):502-508 doi:10.1093/ndt/gfy063.
PMID: 29697822 - 12
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group.
Mekahli D, Müller RU, Marlais M, et al.
Nature reviews. Nephrology 2024; (20(6)):402-420 doi:10.1038/s41581-024-00818-0.
PMID: 38443710 - 13
Blood pressure and glomerular filtration rate in youth with tuberous sclerosis complex.
Vargiami E, Stabouli S, Sidira C, et al.
European journal of pediatrics 2022; (181(4)):1465-1472 doi:10.1007/s00431-021-04333-3.
PMID: 34988664 - 14
Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(7)):1196-1202 doi:10.2215/CJN.08150816.
PMID: 28302901 - 15
Angiographic and volumetric effects of mammalian target of rapamycin inhibitors on angiomyolipomas in tuberous sclerosis.
Sheth RA, Feldman AS, Paul E, et al.
World journal of radiology 2016; (8(3)):308-15 doi:10.4329/wjr.v8.i3.308.
PMID: 27027863 - 16
Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction.
Bardin F, Chevallier O, Bertaut A, et al.
Quantitative imaging in medicine and surgery 2017; (7(1)):8-23 doi:10.21037/qims.2017.01.02.
PMID: 28275556 - 17
Update on the Diagnosis and Management of Renal Angiomyolipoma.
Flum AS, Hamoui N, Said MA, et al.
The Journal of urology 2016; (195(4 Pt 1)):834-46.
PMID: 26612197 - 18
Subependymal Giant Cell Astrocytoma Size Measurement in Tuberous Sclerosis Complex: Noncontrast vs Contrast-Enhanced 3-Dimensional T1-Weighted Magnetic Resonance Imaging (MRI).
Hill BJ, Gadde JA, Palasis S
Journal of child neurology 2019; (34(14)):922-927 doi:10.1177/0883073819867541.
PMID: 31424303 - 19
Subependymal Giant Cell Astrocytoma Without Clinical Evidence of Tuberous Sclerosis Complex: Diagnostic and Molecular Insights-Case Report.
Pickler JGJ, Fronza Junior H, Pedack FR, et al.
Neurology international 2026; (18(7)) doi:10.3390/neurolint18070135.
PMID: 42506057 - 20
[Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T, Niida Y
No shinkei geka. Neurological surgery 2022; (50(1)):111-121 doi:10.11477/mf.1436204536.
PMID: 35169091 - 21
Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry.
Nabbout R, Belousova E, Benedik MP, et al.
Frontiers in neurology 2021; (12()):697467 doi:10.3389/fneur.2021.697467.
PMID: 34566842 - 22
The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex.
Whitney R, Jan S, Zak M, McCoy B
Pediatric neurology 2017; (72()):76-80 doi:10.1016/j.pediatrneurol.2017.04.009.
PMID: 28506505 - 23
Diagnosis and Management of Children With Tuberous Sclerosis Complex.
Dewell C, Chan DL, Sarkozy V, et al.
Journal of paediatrics and child health 2025; doi:10.1111/jpc.70243.
PMID: 41273003 - 24
[Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
Waltereit R, Feucht M, de Vries MC, et al.
Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie 2019; (47(2)):139-153 doi:10.1024/1422-4917/a000604.
PMID: 30080117 - 25
Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.
Prizant H, Hammes SR
Endocrinology 2016; (157(9)):3374-83 doi:10.1210/en.2016-1395.
PMID: 27409646 - 26
Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis.
Tai J, Liu S, Yan X, et al.
Orphanet journal of rare diseases 2024; (19(1)):236 doi:10.1186/s13023-024-03239-1.
PMID: 38877584 - 27
[Sporadic Lymphangioleiomyomatosis (sLAM) and Tuberous Sclerosis Complex (TSC) - Pulmonary Manifestations].
Brakemeier S, Grohé C, Bachmann F, Budde K
Pneumologie (Stuttgart, Germany) 2017; (71(2)):86-95 doi:10.1055/s-0042-111522.
PMID: 27585353 - 28
[Tuberous sclerosis complex: A review].
Pfirmann P, Combe C, Rigothier C
La Revue de medecine interne 2021; (42(10)):714-721 doi:10.1016/j.revmed.2021.03.003.
PMID: 33836894 - 29
EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.
Taveira-DaSilva AM, Moss J
Expert opinion on orphan drugs 2016; (4(4)):369-378 doi:10.1517/21678707.2016.1148597.
PMID: 27833825 - 30
Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.
Di Marco F, Terraneo S, Imeri G, et al.
PloS one 2016; (11(5)):e0155331 doi:10.1371/journal.pone.0155331.
PMID: 27171001 - 31
Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?
Słowińska M, Jóźwiak S, Peron A, et al.
Orphanet journal of rare diseases 2018; (13(1)):25 doi:10.1186/s13023-018-0764-z.
PMID: 29378663 - 32
Cardiac Rhabdomyoma in Adult.
Ghosh S, Milunski MR
Cureus 2021; (13(4)):e14565 doi:10.7759/cureus.14565.
PMID: 34026381 - 33
A Review of Investigations for Patients With Tuberous Sclerosis Complex Who Were Referred to the Tuberous Sclerosis Clinic at The Hospital for Sick Children: Identifying Gaps in Surveillance.
Alsowat D, Zak M, McCoy B, et al.
Pediatric neurology 2020; (102()):44-48 doi:10.1016/j.pediatrneurol.2019.06.018.
PMID: 31362847 - 34
Dermatological manifestations of tuberous sclerosis complex (TSC).
Ebrahimi-Fakhari D, Meyer S, Vogt T, et al.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2017; (15(7)):695-700 doi:10.1111/ddg.13264.
PMID: 28598544 - 35
A dermatological assessment of pediatric patients with tuberous sclerosis complex (TSC).
Nunes BA, Romano AKFG, Pasa Morgan MA, et al.
Anais brasileiros de dermatologia 2024; (99(5)):662-669 doi:10.1016/j.abd.2023.11.004.
PMID: 38658236 - 36
Ophthalmic manifestations of tuberous sclerosis: a review.
Hodgson N, Kinori M, Goldbaum MH, Robbins SL
Clinical & experimental ophthalmology 2017; (45(1)):81-86 doi:10.1111/ceo.12806.
PMID: 27447981 - 37
Neuro-Ophthalmic Characteristics of Patients with Tuberous Sclerosis Complex at a Tertiary Care Referral Centre.
Smith BD, Naseer LA, Rice AE, et al.
Neuro-ophthalmology (Aeolus Press) 2025; (49(3)):241-248 doi:10.1080/01658107.2025.2457587.
PMID: 40190378 - 38
Significant cases of central cusps, enamel pits, and oral fibromas in tuberous sclerosis complex.
Taga H, Yonenaga K, Eno Y, et al.
Odontology 2021; (109(1)):279-283 doi:10.1007/s10266-020-00542-8.
PMID: 32720211 - 39
Oral Manifestations and Quality of Life in Children with Tuberous Sclerosis Complex: A Descriptive Study.
Gosnell ES, Krueger D, Ruck P, et al.
Pediatric dentistry 2021; (43(2)):140-144.
PMID: 33892840 - 40
[Tuberous Sclerosis Complex Detected by Spontaneous Rupture of a Giant Renal Angiomyolipoma : A Case Report].
Kobayashi M, Saito M, Akihama S, et al.
Hinyokika kiyo. Acta urologica Japonica 2017; (63(3)):111-114 doi:10.14989/ActaUrolJap_63_3_111.
PMID: 28331168 - 41
[A Case of Perivascular Epithelioid Cell Tumor (PEComa) of the Uterus Associated with Tuberous Sclerosis Complex Diagnosed by Intra-Abdominal Bleeding from the Uterus].
Taniguchi A, Kakuta Y, Fujita K, et al.
Hinyokika kiyo. Acta urologica Japonica 2019; (65(11)):479-484 doi:10.14989/ActaUrolJap_65_11_479.
PMID: 31902183 - 42
Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.
von Ranke FM, Zanetti G, e Silva JL, et al.
Lung 2015; (193(5)):619-27 doi:10.1007/s00408-015-9750-6.
PMID: 26104489 - 43
Tuberous sclerosis complex for the pulmonologist.
Rebaine Y, Nasser M, Girerd B, et al.
European respiratory review : an official journal of the European Respiratory Society 2021; (30(161)) doi:10.1183/16000617.0348-2020.
PMID: 34348978
This page explains screening and testing after a kidney angiomyolipoma raises concern for TSC; it is for informational purposes only and does not constitute medical advice. Your TSC care team should tailor testing and treatment to your age, symptoms, and results.